tiprankstipranks
Advertisement
Advertisement
Rani Therapeutics Appoints New Chief Financial Officer
PremiumCompany AnnouncementsRani Therapeutics Appoints New Chief Financial Officer
30d ago
Rani Therapeutics appoints Nicholas Maestas as CFO
Premium
The Fly
Rani Therapeutics appoints Nicholas Maestas as CFO
1M ago
Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
Premium
Ratings
Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
2M ago
Rani Therapeutics CFO Svai Sanford to step down
PremiumThe FlyRani Therapeutics CFO Svai Sanford to step down
3M ago
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
Premium
The Fly
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
3M ago
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
Premium
Ratings
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
3M ago
Rani Therapeutics promotes Javadi to Chief Technical Officer
PremiumThe FlyRani Therapeutics promotes Javadi to Chief Technical Officer
6M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100